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The Chemical Manufacturers' Association voluntary test program on phthalate esters is described, and
the results of certain key aspects of the program are presented. Representative phthalate esters were
chosen for genotoxicity testing and peroxisome proliferation screening, and di-2-ethylhexyl phthalate
(DEHP) and its initial metabolic products were tested in the genotoxicity battery. A comparative metab-
olism study was performed with DEHP in the mouse, rat, and cynomologus monkey, togetherwith a study
of the metabolism of DEHP in the rodent at several dose levels, and after prolonged feeding. A standard
testforperoxisome proliferation intherat, employing21daysoffeedingandseveral endpointsisdescribed,
based on DEHP as a reference compound. DEHP is shown to be nongenotoxic in the test battery, and its
initial major metabolites are also nongenotoxic. A nonlinear dose response with respect to the 13-oxidation
of DEHP in the rodent is demonstrated. Quantitative differences exist between the mouse and rat, and
the cynomologus monkey with respect to the 3-oxidation of DEHP, 1-oxidation being a much less used
pathway in the monkey. The significance ofthese results in interpreting the hepatocellular carcinogenesis
of DEHP in the Fischer 344 rat is discussed.
Introduction
The chemical industry has a long-term interest in the
health and environmental effects of phthalic anhydride-
derived plasticizers. Until the beginning of this decade
it was felt that the large volume of production of these
plasticizers (in excess of one billion pounds per annum)
and their extensive use in items of commerce were with-
out any adverse consequences for public health. In fact,
the Chemical Manufacturers Association (CMA) Phthal-
ate EstersPanelhadby 1980confined its attention mostly
to the environmental behavior of phthalate esters.
This circumstance was changed by the findings in the
National Toxicology Program (NTP) bioassay (1), that
bis (or di-) 2-ethylhexyl phthalate (DEHP) was a hepa-
tocellular carcinogen in the Fischer 344 rat and the
B6C3F1 mouse. These results came as a considerable
surprise; the past human use experience with DEHP, its
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structure-activity relationships, its relative chemical in-
ertness, and its lack of biological activity at other than
extremely high intake levels led one to predict that it
would possess no tumorigenic potential. These factors
lead all those concerned, including regulatory agencies
and industry, to adopt a cautious attitude in interpreting
the bioassay results. Additional factors included the ab-
sence ofevidence forgenotoxicity forboth DEHP and the
phthalate ester class as a whole, indications in the sci-
entific literature that substantial differences exist be-
tweenthemetabolismofDEHPintherodentandinother
species (2), and the fact that DEHP is a member of the
hypolipidemic class of rodent peroxisome inducers (3).
The results of the NTP bioassay therefore prompted a
serious effort by CMA to explore the genotoxic, meta-
bolic, and biological properties of DEHP to understand
better the relevance of the bioassay. Also, concern over
theimplicationsofthebioassayresultsforotherphthalate
esters in significant commercial use was raised by the
U.S. Environmental Protection Agency (US-EPA).
AsaresultofnegotiationsbetweenCMAandUS-EPA,
a voluntary program oftesting was undertaken by CMA
to meet both regulatory and industrial concerns. The
objectives of the voluntary program are (a) to confirm
the absence of genotoxicity due to DEHP, (b) to stand-ASTILL ET AL.
Table 1. Phthalate esters and related compounds in the CMA voluntary test program (Production volume >106 lb/yr).
Genotoxicity screening Peroxisome screening
(phthalates) (phthalates)
Genotoxicity Referencea Test Referencea Test
Di-2-ethylhexyl phthalate Di-2-ethylhexyl Dimethyl Di-2-ethylhexyl Di-n-butyl
Mono-2-ethylhexyl phthalate Di-n-butyl Diundecyl
2-Ethylhexanol Diundecyl Diisodecyl
Diisodecyl Diisononyl
Diisononyl Dihexyl, octyl, decyl
Dihexyl, octyl, decyl Diheptyl, nonyl, undecyl
Diheptyl, nonyl, undecyl n-Butylbenzyl
n-Butylbenzyl
aDi-2-ethylhexyl-adipate included: results are reported elsewhere.
ardize test conditions for determining the genotoxic po-
tential ofrepresentative phthalate esters, (c) to establish
a standard peroxisome induction test based on rodent
feeding, (d) to compare representative phthalate esters
asameansofestablishingthelevelofconcernforpotential
health effects, (e) to investigate the metabolic behavior
of DEHP under the conditions of the NTP bioassay in
rats, and (f) to compare the metabolism of DEHP in
rodents and a primate under standard conditions. This
paper reports studies on the genotoxicity of DEHP and
progress in setting up a standard peroxisome induction
test. It provides new information on the metabolism of
DEHP in the rat and a comparative study on the me-
tabolism of DEHP in the Fischer 344 rat, the B6C3Fj
mouse, and the cynomolgus monkey.
CMA Voluntary Test Program
The program was laid out as follows: (1) validation and
optimization for (a) genotoxicity screening and (b) bio-
logical test screening; (2) fate and metabolism studies on
DEHP regarding (a) dose and prefeeding response and
(b) comparative metabolism; (3) screening ofrepresent-
ative phthalate esters. A clear requirement (step 1) was
the selection, validation, and optimization of standard
test procedures for DEHP, certain related compounds,
and representative phthalate esters. The validation and
optimization step involved the selection of appropriate
parameters for screening for peroxisome-inducing activ-
ity, and selecting established protocols for genotoxicity
testing. Representative esters were selected onthebasis
of production volume and structure. The volume cut-off
pointwas 10millionpounds peryear. Thefactorsin struc-
tural consideration were molecular weight (high or low),
linearity or branching of the alcohol side chain, odd or
even number ofatoms in the side chain, and whether the
side chains in an ester were identical or dissimilar.
These factors taken together resulted in the selection
ofeight representative test compounds (Table 1), includ-
ingadditional dimethylphthalate genotoxicitytestingbe-
cause of recent inconclusive findings of its weak muta-
genicity. Optimization andvalidationforbothgenotoxicity
and peroxisome induction were performed with DEHP
and di(2-ethylhexyl) adipate (DEHA) as reference com-
pounds. Definitive information about the genotoxicity of
DEHP was required for interpretive background to the
bioassay results, and the primary metabolites ofDEHP,
i.e., mono(2-ethylhexyl) phthalate (MEHP) and 2-ethyl-
hexanol (2-EH), were also included in the prototype gen-
otoxicity test battery
Genotoxicity Testing
The proposed genotoxicity test battery was set up to
complete the DEHP genotoxic profile and to establish
standard protocols for representative phthalate ester
testing. Asinitiallysetout, thisconsisted ofthestandard
Ames Salmonella typhimurium test, the mouse lym-
phoma L51784Y thymidine kinase assay, the primary rat
hepatocyte unscheduled DNA synthesis test, the mouse
micronucleus (chromosomal aberration) test, and a cell
transformation test using the BALB/3T3 cell line. All
tests included activation where feasible. The rodent S9
fraction used for activation was derived from the Spra-
gue-Dawley Aroclor-treated rat. The test protocols were
those provided for standard tests performed by Litton
Bionetics Inc., Kensington, MD, U.S.A.
The results obtained by running DEHP through this
test battery are given in Table 2. It is seen that over the
very wide dose ranges used in all ofthe tests employed,
no positive results were obtained with DEHP. It is prob-
ably safe to say, that up to the limits of solubility for
DEHP that can be obtained in any of these tests, it is
not genotoxic. In addition, MEHP and 2-EH were tested
in the CMA program in the Ames Salmonella typhi-
murium test, with and without activation, the mouse
micronucleustest, andtheBALB/3T3celltransformation
test, withandwithoutratprimaryhepatocyteactivation.
Both compounds were negative in all tests. Combined
with results in the mouse lymphoma test and the un-
scheduled DNA synthesis test reported earlier (6) and
other studies (7), these results strongly suggest that
DEHPanditsprimarymetabolites intherodent, MEHP
and 2-EH, are not genotoxic.
The components ofthe test battery selected by CMA,
on the basis ofthese results, were the AmesSalmonella
typhimurium test, the CHO-HGPRT test, and the
BALB 3T3 cell transformation test. CMA is presently
testingtherepresentative estersinthismodifiedbattery
However, the Ames test will be omitted from the CMA
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Table 2. Genotoxicity data on DEHP (CMA Program).
Test Dose range Results
Ames, activation
No 0.15-150 F.L/plate No revertants over background
Yes 0.15-150,L/plate
Mouse lymphoma activation
No 7.8-250 nL/mL No increase in mutant frequency
Yes 7.8-125 nL/mL
Mouse micronucleus
Single dose 5 g/kg No increase in % micronucleated cells
Multiple dose 5 g/kg/day
Unscheduled DNA synthesis 5-1000 nL/mL No significant increase in net nuclear grain
counts
Cell transformation 0.875-21 nL/mL No significant increase in foci
Cell transformation with
primary hepatocytes 6.25-100 nL/mL
battery because the identical compounds are under test
by the NTP (5). The mouse lymphoma test was replaced
by the CHO-HGPRT test because ofthe lesser incidence
of false positives in the latter test, and fewer confusing
problems with interpretation at high levels of cell lethal-
ity.
Biological Screening
In rodents, DEHP, MEHP, 2-EH, and DEHA are
knowntodepress serumtriglyceride andchloresterollev-
els, produce liver enlargement, elevate hepatic catalase
activity, and induce certain microbodies in the liver
known as peroxisomes (8). They are thus thought to be-
long to a class of hypolipidemic compounds that were
identified by Reddy and his associates as beingboth non-
genotoxic and having the potential to induce liver tumors
in rodents (3).
This hypothesis that peroxisome induction and rodent
tumorigenesis arerelatedhasbeenextensively discussed
at this and at other meetings on phthalate esters. While
thereismuchevidence infavorofthecorrelation, at pres-
ent no mechanism has been discovered that directly re-
lates the observed physiological changes with liver tu-
morigenesis. As has been pointed out, the phenomenon
may not occur in primates.
The primary biochemical and morphological change in
the target organ for DEHP oncogenesis, the liver, is a
derangement of lipid metabolism as manifested by the
changes discussed above. In screening the selected rep-
resentative esters for their possible oncogenic potential,
CMA proposed a research program to determine if, in
fact, phthalate esters could be graded for their effects
on rodent hepatic lipid metabolism. The parameters es-
tablished for the exploratory screening tests are hepatic
catalase, liepatic acetylcarnitine transferase, cytochem-
ical and morphological parameters on liver, serum tri-
glyceride, serum cholesterol, and serum total lipids. The
hepatic catalase and hepatic acetylcarnitine transferase
havebeenreplacedbycyanide-insensitive palmitoyl coen-
zyme A oxidation and lauryl hydroxylase (w, w - 1). It
was the intention to see if these could be incorporated
into a short feeding test with the Fischer 344 rat, using
DEHP and DEHA as reference compounds. The initial
parameters were liver size, serum lipid and cholesterol
levels, liver catalase and acetylcarnitine transferase ac-
tivities, and cytochemical and morphological measure-
ments on liver cells. The enzyme systems were those
considered most representative of liver peroxisome ac-
tivity at the time of setting up the experiment.
The prototype feeding study employed three dietary
dose levels and a control level, with five each ofmale and
female rats at each level. Sacrifice points for measure-
ments were at 1 or 3 weeks after feeding with the ref-
erence compound, and after 3 weeks of feeding followed
bya2-weekrecoveryperiod. Theintakelevelswerethose
employed in the NTP bioassay with an additional lower
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FIGURE 1. Relative liver weights. Fischer 344 rats received DEHP
inthe diet at the dose levelindicatedfor 1 and 3weeks, and 3weeks
followed by a 2-week recovery.
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intake level of 0.1%. These studies were performed for
CMa by the Midwest Research Institute, Kansas City,
MO.
This communication will describe the results with
DEHP only. Cumulative liver weights in serially sacri-
ficed animals are given in Figure 1. It is clear that at
the dose levels in the NTP study, dramatic increases in
liver weight appear for both sexes within a few days of
the onset of feeding. These increases are reversible, as
they rapidly decline after the cessation of feeding of
DEHE In addition, the 0.1% dose level did not induce
significant liver enlargement in female rats, and the in-
creased weight at the 3-week point in the male rat may
be statistically significant because ofthe drop in control
liver weights.
The effect ofthis regimen on serum lipids is presented
in Figure 2. All three dose levels depressed serum tri-
glyceride levels, while the effect on cholesterol levels in
males and females was somewhat less marked. However,
in the withdrawal period, all levels reverted to normal.
Effects on marked enzyme activities are given in Fig-
ures 3 and 4. It is seen that in general, carnitine acetyl
transferase showed marked increases in specific activity
for all dose levels at 1 week after the onset of feeding
(Fig. 3). This effect was maintained for the two upper-
most dose levels after 3 weeks of feeding. This enzyme
returned to nearly nonnal values during the withdrawal
period. Hepatic catalase was evidently less responsive to
DEHP feeding (Fig. 4). It showed a fairly high normal
specific activity that was widely variable. Increases pro-
ducedbyfeedingwereusuallylessthandoublethecontrol
level. The range ofvariability from rat to rat for a given
datapoint was alsounusually wide. Although some dose-
associated elevations occurred and specific activities ap-
parently reverted to normal when elevated, it was felt
that the catalase activity determination was of qualita-
tive value only. The test laboratory also reported cyto-
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FIGURE 3. DEHP and hepatic carnitine acetyltransferase (CAT).
Fischer 344 rats received DEHP in the diet at the dose level in-
dicatedfor 1 and3weeks, and3weeksfollowedbya2-weekrecovery.
chemical and morphological results; dose-related in-
creases in the numbers of hepatocellular peroxisomes
were observed. These experiments indicated that stand-
ardized conditions for measuring the required parame-
ters could be achieved and that a 21-day feeding is ade-
quate to produce dose-related changes. As a result of
discussions at the CMA Phthalate Workshop in 1983, the
enzymemarkers were changed tocyanideinsensitive pal-
mitoyl coenzyme A oxidation and microsomal lauryl hy-
droxylase activity Both of these systems have been
showntobemuchmore specificallyrelated toperoxisome
induction than the earlier enzyme markers (9,10). Work
- _ Conro
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FIGURE 2. DEHP and hypolipidemia. Fischer 344 rats received
DEHP in the diet at the dose level indicated for 1 and 3 weeks, and
3 weeks followed by a 2-week recovery.
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FIGURE 4. DEHP and hepatic catalase. Fischer 344 rats received
DEHP in the diet at the dose level indicated for 1 and 3 weeks, and
3 weeks followed by a 2-week recovery.
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induction than the earlier enzyme markers (9,10). Work
in progress at the British Industrial and Biological Re-
search Association (BIBRA) has in fact confirmed the
original validation study performed at the Midwest Re-
search Institute, established thecorrelation ofdoselevels
with the new enzyme markers, and allowed us to estab-
lish dose ranges for testing the selected representative
phthalate esters. Testing of these is now underway at
BIBRA in the screening system.
Metabolism and Pharmacokinetic
Studies
Effects of Dose Variability and Prolonged
Feeding
The extensive studies on the metabolism of DEHP in
the rat after administration by gavage have been thor-
oughly reviewed at previous conferences on phthalate es-
ters, andinthisconference. ThepioneeringworkofAlbro
(2,11), and the more recent work ofLhuguenot et al. (12),
have established the salient features of DEHP absorp-
tion, metabolism, and elimination. The convention for
numbering the metabolites as established by Albro has
now become accepted as a shorthand way ofreferring to
them rather than by their complex structural nomencla-
ture.
Although these accounts of metabolism were reason-
ably complete, two important issues relating to the NTP
bioassay needed clarification. First, most ofthe existing
studies were performed by gavage intake with single
doses. In fact, we need to know the effects of incorpo-
rating DEHP into the diet, ofprolonged feeding, and of
varying the intake, on the uptake and metabolism of
DEHP Second, aninterspecies comparisonusing similar
doses and dosing regimens was needed to confirm the
indications in the literature that primates and rodents
metabolized DEHP in a significantly different manner.
Theprocedures forthe dietaryfeedingstudy aregiven
in Table 3. This work was performed byArthurD. Little
Inc., Cambridge, MA. The study design called for up to
21 daysfeedingofunlabeledDEHP atthreeintakelevels,
the upper two of which were those used in the NTP
bioassay. Labeled DEHP was administered in the diet at
the corresponding intake level at days 1, 7, and 21. Ex-
creta and expired air were collected for analysis for the
96-hr period following feeding of the labeled compound.
Table 3. Protocol: fate of DEHP after dietary intake.
Parameter
Compound 14C-DEHP
Species F344 rat, M
Intake level 2,000, 6,000, 12,000 ppm DEHP
Duration 21 days feeding
Dosing Diet at 1, 7, 21 days
Collections 12, 24, 48, 96 hr. after labeled compound CO2,
urine, feces
Sacrifice Selected rats 1 day after each labeled dose
Table 4. Distribution ofradioactivity after 14C-DEHP uptake by
Fischer 344 rats as % of dose.
Distribution oflabel,
% ofdose after prior feeding
Dose, ppm Exereta 0 6 days 20 days
1000 U 53 53 53
F 38 36 35
6000 U 62 64 66
F 27 30 26
12000 U 66 69 68
F 27 24 28
These collections were made at discrete intervals, but
collections were pooled for metabolic identification. Me-
tabolites were detected and quantitated both before and
after glucuronide and sulfate conjugate hydrolysis. The
detection procedures included high-pressure liquid chro-
matography and gas chromatography-mass spectrome-
try.
A study ofthis type generates a large amount ofdata,
and this report will highlight only the more significant
findings. The distribution ofthe radiolabel in excreta is
given in Table 4. The earlier gavage studies suggested
that conversion of DEHP to MEHP in the gastrointes-
tinal tract and uptake of DEHP were rate-limited or
saturable steps. It is evident that when DEHP is ad-
ministered in the diet these limiting mechanisms are not
invoked, presumablybecausethe amountofDEHPinthe
intestinal tract is too low. In fact, an apparently higher
proportion of radioactivity is eliminated in the urine at
the 12,000 ppm intake level than at the 1000 ppm level.
The proportion of the dose eliminated in the feces also
may drop with increased dose. At the dose levels en-
countered in the NTP bioassay, however, no dose-related
changes in uptake or absorption were seen.
Profiles ofthe metabolites ofDEHP were obtained for
all the pooled urine collections. It was thus possible to
ascertain any quantitative or qualitative changes in met-
abolic pattern with duration offeeding and size ofdose.
It will be recollected that in the Albro scheme ofmetab-
olism two important routes for side chain oxidation were
suggested. One ofthese (Fig. 5) began with metabolite
DEHP
\shydrolyze
MEHP
CA3 -oxidation
Metabolite X
Metabolite V
/ -oxidation
Metabolite I
FIGURE 5. Conversion of DEHP to metabolite I. Metabolites are
numbered according to Albro based on the metabolism of DEHP
in the rat.
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X, which is formed from DEHP by hydrolysis and ter-
minal common carbon oxidation. Metabolite X in turn is
oxidized to metabolite V, which then enters the (-oxi-
dationpathwaytobe converted tometabolite I. Asecond
pathway (not pictured) also starts with MEHP, and by
penultimate carbon oxidation yields metabolites VI and
III.
Upon examination oftheurinary metabolic profiles, no
qualitative differences were seenwhichcouldbeascribed
to variations in intake level or duration offeeding. How-
ever, qualitative differences in the percentages ofmetab-
olites I and V were found (Table 5). At 1000 ppm, the
output of metabolite I, the end product of (-oxidation,
approximately doubles by day 6 offeeding. The propor-
tion of metabolite V is unchanged. At 6000 ppm, the
proportion ofmetabolite V produced without prefeeding
is increased from that seen at 1000 ppm. A striking in-
crease in the amount ofmetabolite I is seen after 6 days
ofprefeeding, with a corresponding fall in the amount of
metabolite V At 12,000 ppm, the same phenomenon is
seen, but with slightly larger amounts of production of
metabolite V without prefeeding, and of metabolite I
with prefeeding.
It is clear that nonlinear changes in the production of
these metabolites associated with terminal carbon and
(3-oxidation areoccurringas aresult ofprolonged feeding
and increased DEHP intake. It is of interest that the
penultimate C-atom route of oxidation does not appear
to be affected by these procedures to the same extent
as the terminal C-route.
The biological studies on DEHP described above in-
dicated that the feeding ofDEHP over a dose range and
for a similar duration to that in these metabolic studies
produced liver weight increases, serum lipid depression,
increased activity ofliveroxidative enzyme systems, and
induction ofperoxisomes. Selected animalswereremoved
from these metabolic studies and sacrificed. The relative
liver weights at sacrifice points and dose levels which
correspond to those in the metabolic study are given in
Table 6. These values agree with those found in the biol-
ogic studies and also indicate a correlation between in-
creased liver weight and the increased output of (3-oxi-
dation metabolites from DEHP
This enhancement of beta oxidation may have consid-
erable significance in suggesting amechanism for DEHP
hepatocellular carcinogenesis (Fig. 6). Undernormal cir-
Table 5. Metabolites of DEHP in the rat responding to dose and
duration ofprefeeding as % ofdose.
Exposulre, Metabolites responding, % of dose
Dose, ppm days I V IX
1000 0 5 13 10
6 11 12 8
20 12 11 7
6000 0 8 21 10
6 25 9 7
20 26 8 6
12000 0 8 24 9
6 32 10 5
20 31 7 6
Table 6. Fate and metabolism studies with DEHP: liver weights.
Relative liver weight
Dose, ppm 1 day 7 days 21 days
1000 7.24 8.62 9.06
6000 7.08 9.50 10.98
12000 6.87 10.51 12.16
0 8.71
cumstances, metabolite V would proceed to metabolite
I through the mitochondrial (3-oxidation processes. How-
ever, athighdoses, underconditionsofprolongedfeeding,
the overload ofmetabolite V may pass through the per-
oxisomal (3-oxidation pathway. This produces hydrogen
peroxide, unlike the (-oxidation pathway in the mito-
chondria. This in turn may be regarded as a substance
capable of producing further cellular damage, including
alterations in DNA. While this hypothesis is unproven,
itisreasonabletoconcludethathigh dosesandprolonged
feeding of DEHP produce a marked disturbance in the
lipid oxidation processes in the liver. As the liver is the
only organ that shows aneoplastic response to DEHP in
the rat, it is reasonable to suppose that the two phenom-
ena may be related.
These relationships, as elucidated by the CMA study,
are summarized graphically in Figure 7. This three-di-
mensional figure combines the prefeeding DEHP intake
with the labeled dose intake and the duration of pre-
feeding. The shaded area indicates where increased (-
oxidation of DEHP occurs. It is clear that the greatest
amount of this activity was found at the DEHP intake
levelof12,000ppmforfeedingperiodsinexcessof6days.
Adifferentialmetabolicresponseisclearlydemonstrated
for the dose levels employed in the NTP bioassay. The
biologicalstudiesalsotargetthesedosesasbeingmarked
by increased responses in the parameters associated
with peroxisome induction.
Comparative Metabolism of DEHP
A second major aspect ofthe CMA metabolic studies
concerned the definition ofanyspecies differences which
DEHP
MEHP
Metabolite V
Mltochondrial Proxbomai
0 -oxidation 0-oxidation
Metabolite I
Eliminated
Electon Tport Chain; no peroxide
ProducUon of hydrogen peroxide
FIGURE 6. Routes of conversion ofmetabolite V to metabolite I and
their possible significance for rodent hepatocellular carcinogenesis.
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FIGURE 7. Graphical representation of intake levels, dose levels and
periods ofprefeeding in the rat metabolism study. Horizontal bars
are duration ofprefeeding. Blocked-in portion represents the doses,
intake levels and prefeeding periods for nonlinear formation of me-
tabolite I.
exist in the metabolism of DEHP Clearly, these differ-
ences canplay akeyroleinunderstandingthesignificance
of the bioassay findings for man.
Previous studies by Albro (11) had indicated that
DEHP metabolites in the rat were mostly dicarboxylic
acids with a minor glucuronide component. In man and
the monkey, metabolites tended to be alcohols and were
extensively conjugated as glucuronides. However, consid-
erable differences in routes of administration and dose
levels exist for these studies which make direct compar-
ison difficult.
The protocols proposed by CMA (Table 7) provide for
comparison ofthe metabolism of a single dose oflabeled
DEHP in male Fischer 344 rats, the cynomolgous mon-
keys and B6C3F1 mice. A 100 mg/kg dose was given by
gavage, and urine and feces were collected periodically.
Metabolite identification was performed onthe pooled 96-
hr urine using the techniques already worked out in the
dose-response and feeding study described above.
Similar qualitative metabolic profiles were found in all
three species (Table 8), and, because of the complexity
Table 7. Protocol: comparative metabolism of single dose of "4C-
DEHP.
Parameter
Species F344 Rat, M. cynomolgous monkey, M.
B6C3F' mouse, M.
Dose 100 mg/kg, single gavage
Collections Urine and feces; 12, 24, 48, 96 hr.
Sacrifice 96 hr; tissues processed and counted
Metabolite identifica- Pooled 96-hr urine GC-MS, HPLC, enzymic
tion hydrolysis
Table 8. Comparative metabolic studies on DEHP (CMA): 100
mg/kg 14C-DEHP, % of radioactivity.
% ofradioactivity
Cynomolgus
Metabolite monkey Rat Mouse
Urine MEHP 11 - 17
Phthalic acid 2 2 13
Metabolite I 0.5 11 13
Metabolite V 25 29 1
Metabolite X 9 4 2
Conjugates 15 1 5
Feces DEHP 34 20 16
MEHP 3 8 24
of these pathways, only the salient details are given.
Underconditionsoforalgavage, itisevidentthatallthree
species produce significant amounts ofacidic metabolites
and that conjugation is not the major pathway in any of
them. Furthermore, all three species extensively hydro-
lyze DEHP in the gastrointestinal tract, and their major
metabolites arise from MEHP The key difference ap-
pears to lie in the negligible output ofmetabolite I in the
monkey as compared with the rat and the mouse. Infact,
in the important sequence of metabolites X, V, and I,
there appears to be a buildup of metabolite V in the
monkey with almost no metabolite I. In contrast, both
the rat and the mouse were able to produce metabolite
I.
These results suggest that DEHP is not handled by
the ,-oxidation pathwayinthemonkeyand, byextension,
in other primates. This may represent a key distinction
between the primate and the rodent of importance in
assessingthe results ofthe bioassay. It should be pointed
out, however, that we do not know whether prolonged
feeding of a high dose of DEHP to the monkey would
produce the stimulation of this pathway as seen in the
rodent. Suggestive evidence that DEHP is not a potent
peroxisome inducer in subhuman primates such as the
marmoset (13) would indicate that this is not likely to be
the case.
Conclusions
This survey of the interim results of the CMA pro-
gram, while necessarily incomplete in many details, in-
dicates that satisfactory progress is being made in
achieving the objectives ofthe voluntary test program.
It is now clear that DEHP is nongenotoxic, and that
under in vivo conditions its major initial metabolites are
also not genotoxic. Satisfactory experimental conditions
have been worked out for screening representative
phthalate esters for their effects on the oxidative pro-
cesses ofthe rat liver. A differential metabolic response
has been demonstrated with prolonged feeding over a
range of intake levels in DEHP in the rodent. It is in-
teresting that this response is associated with the dis-
turbances in lipid metabolism already demonstrated in
our biological studies and those of others. Finally, while
there are no qualitative species differences in the me-
tabolism ofDEHP, quantitative differences which do ex-
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ist between primates and rodents lie in the area of me-
tabolite oxidation.
It would be desirable to see further studies on the
relationship between peroxisome proliferation androdent
tumorigenesis and on the effects of lipid oxidation pro-
cesses in the monkey ofprolonged feeding ofa high dose
of DEHP
These studies were carried out under the supervision of the Toxi-
cology Research Task Group, Phthalate Ester Panel, Chemical Man-
ufacturers Association, Washington, DC, U.S.A. Theywere performed
at Arthur D. Little, Inc., the Midwest Research Institute, and Litton
Bionetics, Inc.
The help and counsel of W Broddle, George DiVincenzo, Terry Pul-
len, and Sandra Reiss are acknowledged.
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